These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 33468087)
1. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475 [TBL] [Abstract][Full Text] [Related]
4. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials. Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130 [TBL] [Abstract][Full Text] [Related]
5. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis. Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737 [TBL] [Abstract][Full Text] [Related]
6. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Natori A; Ethier JL; Amir E; Cescon DW Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis. Bai J; Yao X; Pu Y; Wang X; Luo X Front Oncol; 2023; 13():1245650. PubMed ID: 37954087 [TBL] [Abstract][Full Text] [Related]
8. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453 [TBL] [Abstract][Full Text] [Related]
9. Taxanes for adjuvant treatment of early breast cancer. Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Taşçı EŞ; Kutlu Y; Ölmez ÖF; Mutlu AU; Gündoğdu Y; Seyyar M; Şahin E; Çabuk D; Majidova N; Uğurlu İ; Demirci A; Aydın D; Çavdar E; Bayram S; Yıldırım N; Karataş F; Eryılmaz MK; Çağlayan D; Menekşe S; Kut E; Arak H; Keser M; Sunar V; Perkin P; Şakalar T; Oyan B; Sönmez Ö; Özer L; Yıldız İ Expert Opin Pharmacother; 2024 Mar; 25(4):477-484. PubMed ID: 38568074 [TBL] [Abstract][Full Text] [Related]
11. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; ; ; J Clin Oncol; 2020 Jan; 38(3):203-213. PubMed ID: 31804894 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis. Xun X; Cao Q; Hong P; Rai S; Zhou Y; Liu R; Hu H Front Oncol; 2022; 12():899423. PubMed ID: 35875141 [TBL] [Abstract][Full Text] [Related]
13. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131 [TBL] [Abstract][Full Text] [Related]
14. The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer-A Meta-Analysis. Zhang Z; Ma K; Li J; Guan Y; Yang C; Yan A; Zhu H Front Pharmacol; 2021; 12():771839. PubMed ID: 34867401 [No Abstract] [Full Text] [Related]
15. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Chen QJ; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Su YH; Hua X; Wang XY; Hong RX; Jiang KK; Song CG; Huang ZZ; Shi W; Zhong YY; Yuan ZY; JAMA; 2021 Jan; 325(1):50-58. PubMed ID: 33300950 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. Zhang ZC; Xu QN; Lin SL; Li XY PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288 [TBL] [Abstract][Full Text] [Related]
17. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695 [TBL] [Abstract][Full Text] [Related]
18. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience. Singareeka Raghavendra A; Liu D; Shen Y; Barcenas CH; Ueno NT; Giordano S; Tripathy D; Sri Karuturi M Breast Cancer Res Treat; 2024 Aug; 207(1):81-90. PubMed ID: 38916821 [TBL] [Abstract][Full Text] [Related]
20. Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. Pathak N; Sharma A; Elavarasi A; Sankar J; Deo SVS; Sharma DN; Mathur S; Kumar S; Prasad CP; Kumar A; Batra A Breast; 2022 Aug; 64():7-18. PubMed ID: 35462344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]